Ophthalmic infections/conjunctivitis: Ophthalmic: Instill 1 drop into the conjunctival sac of each eye every 12 hours for 7 days; reassess if infection has not resolved after 7 days
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
Refer to adult dosing.
Ophthalmic infections/conjunctivitis: Children ≥2 years and Adolescents: Refer to adult dosing.
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
1% to 10%: Ophthalmic: Eye irritation (3%; transient)
<1%: Abscess (eyelid), asthenopia, blurred vision (temporary), burning sensation of eyes (transient), chest infection, conjunctival abnormalities (cobblestone appearance of the conjunctival sulcus), decreased appetite, exacerbation of eye infection (conjunctivitis), eye pain, eyelid edema, headache, lacrimation (transient), local hypersensitivity reaction, oral candidiasis, skin rash, sticky sensation of eye, tonsillitis, urinary incontinence, urticaria, vomiting
Hypersensitivity to fusidic acid or any component of the formulation
Concerns related to adverse effects:
• Superinfection: Prolonged use may result in superinfection (including fungal infections). Discontinue use if superinfection occurs; evaluate and treat appropriately.
Special populations:
• Neonates: Not indicated for use in neonatal conjunctivitis.
Dosage form specific issues:
• Benzalkonium chloride: Multidose vials contain benzalkonium chloride; may be absorbed by contact lenses.
Other warnings/precautions:
• Appropriate use: For topical use only; do not inject into the eye. Discontinue use if irritation (other than transient stinging upon administration) develops.
• Contact lenses: Contact lenses should not be worn during treatment.
Not available in the US
Yes
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Suspension, Ophthalmic:
Fucithalmic: 1% (3 g, 5 g) [contains benzalkonium chloride]
Ophthalmic: For ophthalmic use only. Tilt head back, pull down lower eyelid and instill drop into eye. Wash hands before and after instillation; avoid touching tip of applicator to eye or other surfaces. Contact lenses should not be worn during therapy.
Ophthalmic: For ophthalmic use only. Contact lenses should not be worn during therapy. Wash hands before and after instillation. Tilt head back, pull down lower eyelid and instill drop into eye. Avoid touching tip of applicator to eye or other surfaces.
Note: Not approved in the United States.
Ophthalmic infections/conjunctivitis: Treatment of superficial infections of the eye and conjunctiva caused by susceptible organisms (Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae) in adults and pediatric patients ≥2 years of age.
None known.
There are no known significant interactions.
Adverse effects were not observed in animal reproduction studies. Fusidic acid crosses the placenta during systemic administration.
Fusidic acid is present in breast milk following systemic administration. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.
Inhibits protein synthesis by blocking aminoacyl-tRNA transfer to protein in susceptible bacteria.
Absorption: Good; lacrimal fluid concentrations range 15.7-40 mcg/mL and 1.4 mcg-5.6 mcg/mL at 1 hour and 12 hours respectively after administration. Median concentrations of 0.3 mcg/mL (single dose) and 0.8 mcg/mL (repeated dosing) were maintained in aqueous humor over 12 hours (Hansen, 1985).
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟